BioHarvest announces underwritten public offering of common stock

BioHarvest Sciences Inc. (NASDAQ: BHST) announced plans for an underwritten public offering of common stock. The company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of shares offered.

Craig-Hallum serves as the sole managing underwriter for the offering. The completion, size and terms of the offering remain subject to market and other conditions.

BioHarvest stated it plans to use net proceeds for research and development, manufacturing, marketing, advancing its CDMO business unit, debt reduction or refinancing, capital expenditures, and general corporate purposes including working capital funding.

The offering operates under a shelf registration statement on Form F-3 filed with the Securities and Exchange Commission on August 28, 2025, which became effective September 8, 2025. The company will file a preliminary prospectus supplement with the SEC detailing the offering terms.

BioHarvest develops plant-based compounds through its botanical synthesis technology platform without growing the underlying plants. The company operates in two business areas: as a contract development and production organization for customers seeking plant-based compounds, and as a creator of nutraceutical health and wellness products.

You May Also Be Interested In

• Apple alleges defendant in trade secret case against OpenAI accessed power converter circuit schematic while at OpenAI - legal filing
• Lifeward names interim CEO and CFO amid leadership change
• Wellchange Holdings closes $7.5M public offering of Class A shares